AlloVir to wind down PhIII trials for futility and will review strategic alternatives

AlloVir is pondering its corporate future after finding out that its lead antiviral cell therapy candidate is likely ineffective.

The biotech had been testing posoleucel, an off-the-shelf virus-specific T cell therapy, in three separate Phase III trials. At the pre-planned futility analyses, all three independent data safety monitoring boards (DSMBs)…
Click here to view original post

Advertisement — Advertise with Biotech Networks